Alkermes (ALKS)
(Real Time Quote from BATS)
$28.22 USD
-0.13 (-0.46%)
Updated Nov 15, 2024 11:38 AM ET
4-Sell of 5 4
B Value C Growth F Momentum B VGM
Price, Consensus and EPS Surprise
ALKS 28.22 -0.13(-0.46%)
Will ALKS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Other News for ALKS
Bank of America Securities Keeps Their Hold Rating on Alkermes (ALKS)
Alkermes price target raised to $31 from $28 at BofA
Alkermes price target raised by $3 at BofA, here's why
Affinity Asset Advisors, LLC Increases Stake in NextCure Inc
Alkermes price target raised to $40 from $35 at Mizuho